Syllabus
BCOP Prep Course (BCOP)
81 lessons. Online and self-paced.
Oncology Foundations
Core cancer biology, pathophysiology, resistance, testing concepts, and prevention principles that underpin exam-style oncology pharmacotherapy decisions.
- 1Carcinogenesis And Hallmarks
- 2Cancer Types And Kinetics
- 3Tumor Resistance Mechanisms
- 4Mutation Types And Amplification
- 5NGS And Assay Limits
- 6Predictive And Prognostic Tests
- 7Screening And Early Detection
- 8Risk Reduction Strategies
- 9Support And Education Resources
Treatment Planning
Foundational treatment-planning principles including staging context, lines of therapy, guidelines, survivorship, and patient-centered considerations within pharmacist scope.
- 10Curative And Palliative Intent
- 11Line Of Therapy Logic
- 12Guideline Concordant Regimen Support
- 13Performance Status And Frailty
- 14Social Determinants In Oncology
- 15Palliative Goals And End Of Life
- 16Survivorship Care Principles
- 17Nonmalignant Hematology Pharmacotherapy
- 18Transitional Care Coordination
Solid Tumor Therapeutics
High-yield disease-state pharmacotherapy for major solid tumors with emphasis on regimen selection support, biomarkers, sequencing, and pharmacist safety checks.
- 19Breast Cancer Regimen Frameworks
- 20Gynecologic Cancer Systemic Therapy
- 21Hormonal And Targeted Sequencing
- 22Lung Cancer Biomarker Therapy
- 23Colorectal And Hepatobiliary Regimens
- 24Upper GI And Pancreatic Therapy
- 25Genitourinary Cancer Regimens
- 26Melanoma And Skin Therapies
- 27CNS And Rare Tumors
Hematologic Malignancies
Major hematologic malignancy frameworks including leukemias, lymphomas, plasma cell disorders, and transplant or cellular therapy complications.
- 28AML And ALL Regimens
- 29CML And MPN Therapies
- 30CLL Treatment Sequencing
- 31Hodgkin And NHL Regimens
- 32Multiple Myeloma Pharmacotherapy
- 33Cellular Therapy Toxicities
- 34Conditioning And GVHD Prophylaxis
- 35Infection Prophylaxis Frameworks
- 36Transplant Complication Management
Antineoplastic Pharmacology
Mechanisms, PK/PD, class toxicities, administration nuances, and interaction principles across cytotoxic, targeted, hormonal, immune, and cellular therapies.
- 37Alkylators Antimetabolites Anthracyclines
- 38Taxanes Platinum And Topoisomerase
- 39Vinca And Specialty Agents
- 40Tyrosine Kinase Inhibitors
- 41Monoclonal And Antibody Conjugates
- 42Hormonal And Immune Pharmacology
- 43Dosage Forms And Routes
- 44Drug Food And Supplement Interactions
- 45Pharmacogenomic Relevance
Supportive Care
Essential supportive care for nausea, neutropenia, infection prevention, symptom management, and survivorship-oriented medication support.
- 46CINV Prophylaxis Frameworks
- 47Growth Factor Support Logic
- 48Anemia And Thrombocytopenia Support
- 49Febrile Neutropenia Management
- 50Tumor Lysis Prevention
- 51Mucositis Diarrhea And Nutrition
- 52Cancer Pain Pharmacotherapy
- 53Bone Health And Hypercalcemia
- 54End Of Life Symptom Support
Toxicities And Emergencies
Recognition, prevention, grading, and pharmacist-scope management of oncologic toxicities, emergencies, and long-term complications.
- 55Myelosuppression And Infection Risk
- 56Cardiac Pulmonary And Renal Injury
- 57Dermatologic Neurologic And Endocrine Effects
- 58Immune Related Adverse Events
- 59Infusion And Hypersensitivity Reactions
- 60Oncologic Emergency Pharmacotherapy
- 61Secondary Malignancies And Fertility
- 62Chronic Cardiometabolic And Bone Effects
- 63Long Term Monitoring Plans
Calculations Monitoring Safety
Dose calculations, organ function interpretation, regimen verification, hazardous drug handling, and pharmacist action frameworks for safe oncology practice.
- 64BSA Weight And AUC Dosing
- 65Renal And Hepatic Adjustments
- 66Exposure Limits And Cumulative Doses
- 67Pretreatment Parameter Review
- 68Response Assessment Principles
- 69Monitoring Plan Design
- 70Hazardous Drug Handling
- 71REMS Biosimilars And Access
- 72Quality And Error Prevention
Research And Evidence
Clinical trials, statistics, investigational drug management, and evidence interpretation for oncology pharmacists preparing for board-style questions.
- 73Study Designs And Validity
- 74Oncology Endpoints And Outcomes
- 75Drug Approval And Labeling
- 76Risk Measures And NNT
- 77P Values And Confidence Intervals
- 78Power Multiplicity And Subgroups
- 79Research Ethics And Consent
- 80IRB IEC And Trial Oversight
- 81Investigational Drug Management






